1	State of Arkansas	A Bill	
2	93rd General Assembly	A DIII	
3	Regular Session, 2021		HOUSE BILL 1570
4			1 01 1 0 1 0
5	By: Representatives Lundstrum, Bark	•	_
6	Cooper, Cozart, Crawford, Dalby, Do	•	•
7	Hollowell, Ladyman, Lowery, Lynch,		
8	Pilkington, Ray, Richmond, Slape, B.	Smith, Speaks, Tollett, Tosh, Uno	derwood, vaugnt, warren,
9	Watson, Wing	Doolsham Dladaga D. Davis I. Er	valiah Cilmana V Hamman Hill
10	By: Senators A. Clark, B. Ballinger, I		
11	Irvin, B. Johnson, M. Johnson, Raper	t, Rice, G. Stubbleffeld, D. Wallac	ee
12	Tr.	or An Act To Be Entitled	
13		E THE ARKANSAS SAVE ADOLES	COENTIC EDOM
14			
15	EXPERIMENTATION	(SAFE) ACT; AND FOR OTHER	K PURPUSES.
16 17			
17		Subtitle	
19	ጥር ርዕፍለጥር ነ	THE ARKANSAS SAVE ADOLESC	FNTC
20		IMENTATION (SAFE) ACT.	ENIS
21	FROM EXPER	IMENIATION (SAFE) ACT.	
22			
23	BE IT ENACTED BY THE GENERAL	. ASSEMBLY OF THE STATE O	F ARKANSAS•
24	DE 11 EMIGIES SI THE CENTRAL	THOUSE OF THE STATE OF	i mamono.
25	SECTION 1. Title.		
26		vn and may be cited as the	e "Arkansas Save
27	Adolescents from Experimenta		
28	•		
29	SECTION 2. <u>Legislativ</u>	ve findings.	
30	The General Assembly f	finds that:	
31	(1) Arkansas ha	as a compelling government	t interest in protecting
32	the health and safety of its	s citizens, especially vu	lnerable children;
33	<u>(2)(A) Only a s</u>	small percentage of the A	merican population
34	experiences distress at ider	ntifying with their biolog	gical sex.
35	(B) Accor	rding to the American Psyc	chiatric Association,
36	"For natal adult males, prev	valence ranges from 0.005°	% to 0.014%, and for

1	natal females, from 0.002% to 0.003%.";
2	(3) For the small percentage of children who are gender
3	nonconforming or experience distress at identifying with their biological
4	sex, studies consistently demonstrate that the majority come to identify with
5	their biological sex in adolescence or adulthood, thereby rendering most
6	physiological interventions unnecessary;
7	(4) Furthermore, scientific studies show that individuals
8	struggling with distress at identifying with their biological sex often have
9	already experienced psychopathology, which indicates these individuals should
10	be encouraged to seek mental health services to address comorbidities and
11	underlying causes of their distress before undertaking any hormonal or
12	surgical intervention;
13	(5) Even among people who have undergone inpatient gender
14	reassignment procedures, suicide rates, psychiatric morbidities, and
15	mortality rates remain markedly elevated above the background population;
16	(6)(A) Some healthcare providers are prescribing puberty-
17	$\underline{\text{blocking drugs, such as gonadotropin-releasing hormone analogues, in order} \ \underline{\text{to}}$
18	$\underline{\text{delay the onset or progression of puberty in children who experience distress}}$
19	at identifying with their biological sex.
20	(B) The prescribing of puberty-blocking drugs is being
21	done despite the lack of any long-term longitudinal studies evaluating the
22	$\underline{\text{risks and benefits of using these drugs for the treatment of such distress or}}$
23	<pre>gender transition;</pre>
24	(7) Healthcare providers are also prescribing cross-sex hormones
25	for children who experience distress at identifying with their biological
26	sex, despite the fact that no randomized clinical trials have been conducted
27	on the efficacy or safety of the use of cross-sex hormones in adults or
28	children for the purpose of treating such distress or gender transition;
29	(8) The use of cross-sex hormones comes with serious known
30	risks, such as:
31	(A) For biological females:
32	(i) Erythrocytosis, which is an increase in red
33	blood cells;
34	(ii) Severe liver dysfunction;
35	(iii) Coronary artery disease, including heart
36	attacks;

1	(iv) Cerebrovascular disease, including strokes;
2	(v) Hypertension;
3	(vi) Increased risk of breast and uterine cancers;
4	<u>and</u>
5	(vii) Irreversible infertility; and
6	(B) For biological males:
7	(i) Thromboembolic disease, including blood clots;
8	(ii) Cholelithiasis, including gallstones;
9	(iii) Coronary artery disease, including heart
10	attacks;
11	(iv) Macroprolactinoma, which is a tumor of the
12	pituitary gland;
13	(v) Cerebrovascular disease, including strokes;
14	(vi) Hypertriglyceridemia, which is an elevated
15	level of tryglycerides in the blood;
16	(vii) Breast cancer; and
17	(viii) Irreversible infertility;
18	(9) Genital and nongenital gender reassignment surgeries are
19	generally not recommended for children, although evidence indicates referrals
20	for children to have such surgeries are becoming more frequent;
21	(10)(A) Genital gender reassignment surgery includes several
22	irreversible invasive procedures for males and females and involves the
23	alteration of biologically healthy and functional body parts.
24	(B) For biological males, surgery may involve:
25	(i) Genital reconstruction including penectomy,
26	which is the removal of the penis;
27	(ii) Orchiectomy, which is the removal of the
28	testicles;
29	(iii) Vaginoplasty, which is the construction of a
30	vagina-like structure, typically through a penile inversion procedure;
31	(iv) Clitoroplasty, which is the construction of a
32	clitoris-like structure; and
33	(v) Vulvoplasty, which is the construction of a
34	vulva-like structure.
35	(C) For biological females, surgery may involve:
36	(i) A hysterectomy or oophorectomy;

1	(ii) Reconstruction of the urethra;
2	(iii) Genital reconstruction including
3	metoidioplasty or phalloplasty, which is the construction of a penis-like
4	structure;
5	(iv) Vaginectomy, which is the removal of the
6	vagina;
7	(v) Scrotoplasty, which is the construction of a
8	penis-like and scrotum-like structure; and
9	(vi) Implantation of erection or testicular
10	<pre>prostheses;</pre>
11	(11) The complications, risks, and long-term care concerns
12	associated with genital gender reassignment surgery for both males and
13	females are numerous and complex;
14	(12)(A) Nongenital gender reassignment surgery includes various
15	invasive procedures for males and females and also involves the alteration or
16	removal of biologically normal and functional body parts.
17	(B) For biological males, this surgery may involve:
18	(i) Augmentation mammoplasty;
19	(ii) Facial feminization surgery;
20	(iii) Liposuction;
21	(iv) Lipofilling;
22	(v) Voice surgery;
23	(vi) Thyroid cartilage reduction;
24	(vii) Gluteal augmentation;
25	(viii) Hair reconstruction; and
26	(ix) Other aesthetic procedures.
27	(C) For biological females, this surgery may involve:
28	(i) A subcutaneous mastectomy;
29	<pre>(ii) Voice surgery;</pre>
30	(iii) Liposuction;
31	(iv) Lipofilling;
32	(v) Pectoral implants; and
33	(vi) Other aesthetic procedures;
34	(13)(A) It is an accepted principle of economics and public
35	policy that when a service or product is subsidized or reimbursed, demand for
36	that service or product is increased

1	(B) Between 2015 and 2016, gender reassignment surgeries
2	increased by nearly twenty percent (20%) in the United States;
3	(14) It is of grave concern to the General Assembly that the
4	medical community is allowing individuals who experience distress at
5	identifying with their biological sex to be subjects of irreversible and
6	drastic nongenital gender reassignment surgery and irreversible, permanently
7	sterilizing genital gender reassignment surgery, despite the lack of studies
8	showing that the benefits of such extreme interventions outweigh the risks;
9	<u>and</u>
10	(15) The risks of gender transition procedures far outweigh any
11	benefit at this stage of clinical study on these procedures.
12	
13	SECTION 3. Arkansas Code Title 20, Chapter 9, is amended to add an
14	additional subchapter to read as follows:
15	
16	Subchapter 15 - Arkansas Save Adolescents from Experimentation (SAFE) Act
17	
18	20-9-1501. Definitions.
19	As used in this subchapter:
20	(1) "Biological sex" means the biological indication of male and
21	female in the context of reproductive potential or capacity, such as sex
22	chromosomes, naturally occurring sex hormones, gonads, and nonambiguous
23	internal and external genitalia present at birth, without regard to an
24	individual's psychological, chosen, or subjective experience of gender;
25	(2) "Cross-sex hormones" means:
26	(A) Testosterone or other androgens given to biological
27	females in amounts that are larger or more potent than would normally occur
28	naturally in healthy biological sex females; and
29	(B) Estrogen given to biological males in amounts that are
30	larger or more potent than would normally occur naturally in healthy
31	biological sex males;
32	(3) "Gender" means the psychological, behavioral, social, and
33	cultural aspects of being male or female;
34	(4) "Gender reassignment surgery" means any medical or surgical
35	service that seeks to surgically alter or remove healthy physical or
36	anatomical characteristics or features that are typical for the individual's

T	biological sex, in order to instill or create physiological or anatomical
2	characteristics that resemble a sex different from the individual's
3	biological sex, including without limitation, genital or nongenital gender
4	reassignment surgery performed for the purpose of assisting an individual
5	with a gender transition;
6	(5) "Gender transition" means the process in which a person goes
7	from identifying with and living as a gender that corresponds to his or her
8	biological sex to identifying with and living as a gender different from his
9	or her biological sex, and may involve social, legal, or physical changes;
10	(6)(A) "Gender transition procedures" means any medical or
11	surgical service, including without limitation physician's services,
12	inpatient and outpatient hospital services, or prescribed drugs related to
13	gender transition that seeks to:
14	(i) Alter or remove physical or anatomical
15	characteristics or features that are typical for the individual's biological
16	sex; or
17	(ii) Instill or create physiological or anatomical
18	characteristics that resemble a sex different from the individual's
19	biological sex, including without limitation medical services that provide
20	puberty-blocking drugs, cross-sex hormones, or other mechanisms to promote
21	the development of feminizing or masculinizing features in the opposite
22	biological sex, or genital or nongenital gender reassignment surgery
23	performed for the purpose of assisting an individual with a gender
24	transition.
25	(B) "Gender transition procedures" do not include:
26	(i) Services to persons born with a medically
27	verifiable disorder of sex development, including a person with external
28	biological sex characteristics that are irresolvably ambiguous, such as those
29	born with 46 XX chromosomes with virilization, 46 XY chromosomes with
30	undervirilization, or having both ovarian and testicular tissue;
31	(ii) Services provided when a physician has
32	otherwise diagnosed a disorder of sexual development that the physician has
33	determined through genetic or biochemical testing that the person does not
34	have normal sex chromosome structure, sex steroid hormone production, or sex
35	steroid hormone action;
36	(iii) The treatment of any infection, injury,

1	disease, or disorder that has been caused by or exacerbated by the
2	performance of gender transition procedures, whether or not the gender
3	transition procedure was performed in accordance with state and federal law
4	or whether not funding for the gender transition procedure is permissible
5	under this subchapter; or
6	(iv) Any procedure undertaken because the individual
7	suffers from a physical disorder, physical injury, or physical illness that
8	would, as certified by a physician, place the individual in imminent danger
9	of death or impairment of major bodily function unless surgery is performed;
10	(7) "Genital gender reassignment surgery" means a medical
11	procedure performed for the purpose of assisting an individual with a gender
12	transition, including without limitation:
13	(A) Surgical procedures such as penectomy, orchiectomy,
14	vaginoplasty, clitoroplasty, or vulvoplasty for biologically male patients or
15	hysterectomy or ovariectomy for biologically female patients;
16	(B) Reconstruction of the fixed part of the urethra with
17	or without a metoidioplasty; or
18	(C) Phalloplasty, vaginectomy, scrotoplasty, or
19	implantation of erection or testicular prostheses for biologically female
20	patients;
21	(8) "Healthcare professional" a person who is licensed,
22	certified, or otherwise authorized by the laws of this state to administer
23	health care in the ordinary course of the practice of his or her profession;
24	(9) "Nongenital gender reassignment surgery" means medical
25	procedures performed for the purpose of assisting an individual with a gender
26	transition including without limitation:
27	(A) Surgical procedures for biologically male patients,
28	such as augmentation mammoplasty, facial feminization surgery, liposuction,
29	lipofilling, voice surgery, thyroid cartilage reduction, gluteal
30	augmentation, hair reconstruction, or various aesthetic procedures; or
31	(B) Surgical procedures for biologically female patients,
32	such as subcutaneous mastectomy, voice surgery, liposuction, lipofilling,
33	pectoral implants, or various aesthetic procedures;
34	(10) "Physician" means a person who is licensed to practice
35	medicine in this state;
36	(11) "Puberty-blocking drugs" means gonadotropin-releasing

- l hormone analogues or other synthetic drugs used in biological males to stop
- 2 <u>luteinizing hormone secretion and therefore testosterone secretion</u>, or
- 3 synthetic drugs used in biological females which stop the production of
- 4 <u>estrogens and progesterone</u>, when used to delay or suppress pubertal
- 5 development in children for the purpose of assisting an individual with a
- 6 gender transition; and
- 7 (12) "Public funds" means state, county, or local government
- 8 monies, in addition to any department, agency, or instrumentality authorized
- 9  $\underline{\text{or appropriated under state law or derived from any fund in which such moneys}}$
- 10 <u>are deposited.</u>

11

- 12 <u>20-9-1502.</u> Prohibition of gender transition procedures for minors.
- 13 (a) A physician or other healthcare professional shall not provide
- 14 gender transition procedures to any individual under eighteen (18) years of
- 15 <u>age</u>.
- 16 (b) A physician, or other healthcare professional shall not refer any
- 17 individual under eighteen (18) years of age to any healthcare professional
- 18 for gender transition procedures.
- 19 (c) A physician or other healthcare professional is not prohibited
- 20 <u>from providing any of the following procedures which are not gender</u>
- 21 transition procedures to an individual under eighteen (18) years of age:
- 22 (1) Services to persons born with a medically verifiable
- 23 disorder of sex development, including a person with external biological sex
- 24 characteristics that are irresolvably ambiguous, such as those born with 46
- 25 XX chromosomes with virilization, 46 XY chromosomes with undervirilization,
- 26 or having both ovarian and testicular tissue;
- 27 (2) Services provided when a physician has otherwise diagnosed a
- 28 disorder of sexual development that the physician has determined through
- 29 genetic or biochemical testing that the person does not have normal sex
- 30 <u>chromosome structure</u>, sex steroid hormone production, or sex steroid hormone
- 31 action;
- 32 (3) The treatment of any infection, injury, disease, or disorder
- 33 that has been caused by or exacerbated by the performance of gender
- 34 transition procedures, whether or not the gender transition procedure was
- 35 performed in accordance with state and federal law or whether not funding for
- 36 the gender transition procedure is permissible under this subchapter; or

1	(4) Any procedure undertaken because the individual suffers from
2	a physical disorder, physical injury, or physical illness that would, as
3	certified by a physician, place the individual in imminent danger of death or
4	impairment of major bodily function unless surgery is performed.
5	
6	20-9-1503. Prohibition on use of public funds for gender transition
7	procedures.
8	(a) Public funds shall not be directly or indirectly used, granted,
9	paid, or distributed to any entity, organization, or individual that provides
10	gender transition procedures to an individual under eighteen (18) years of
11	age.
12	(b) Healthcare services furnished in the following situations shall
13	not include gender transition procedures to an individual under eighteen (18)
14	years of age:
15	(1) By or in a healthcare facility owned by the state or a
16	county or local government; or
17	(2) By a physician or other healthcare professional employed by
18	state or a county or local government.
19	(c) Any amount paid by an individual or an entity during a taxable
20	year for provision of gender transition procedures or as premiums for health
21	care coverage that includes coverage for gender transition procedures is not
22	tax-deductible.
23	(d) The Arkansas Medicaid Program shall not reimburse or provide
24	coverage for gender transition procedures to .
25	
26	20-9-1504. Enforcement.
27	(a) Any referral for or provision of gender transition procedures to
28	an individual under eighteen (18) year of age is unprofessional conduct and
29	is subject to discipline by the appropriate licensing entity or disciplinary
30	review board with competent jurisdiction in this state.
31	(b) A person may assert an actual or threatened violation of this
32	subchapter as a claim or defense in a judicial or administrative proceeding
33	and obtain compensatory damages, injunctive relief, declaratory relief, or
34	any other appropriate relief.
35	(c)(l) A person shall bring a claim for a violation of this subchapter
36	no later than two (2) years after the day the cause of action accrues.

T	(2) An individual under eighteen (18) years of age may bring an
2	action throughout their minority through a parent or next friend, and may
3	bring an action in their own name upon reaching majority at any time from
4	that point until twenty (20) years after reaching the age of majority.
5	(d) Notwithstanding any other provision of law, an action under this
6	subchapter may be commenced, and relief may be granted, in a judicial
7	proceeding without regard to whether the person commencing the action has
8	sought or exhausted available administrative remedies.
9	(e) In any action or proceeding to enforce a provision of this
10	subchapter, a prevailing party who establishes a violation of this subchapter
11	shall recover reasonable attorneys' fees.
12	(f)(l) The Attorney General may bring an action to enforce compliance
13	with this subchapter.
14	(2) This subchapter does not deny, impair, or otherwise affect
15	any right or authority of the Attorney General, the State of Arkansas, or any
16	agency, officer, or employee of the state, acting under any law other than
17	this subchapter, to institute or intervene in any proceeding.
18	
19	SECTION 4. Arkansas Code Title 23, Chapter 79, Subchapter 1, is
20	amended to add an additional section to read as follows:
21	23-79-164. Insurance coverage of gender transition procedures for
22	minors prohibited.
23	(a) As used in this section, "gender transition procedures" means the
24	same as defined in § 20-9-1501.
25	(b) A health benefit plan under an insurance policy or other plan
26	providing healthcare coverage in this state shall not include reimbursement
27	for gender transition procedures for a person under eighteen (18) years of
28	age.
29	(c) A health benefit plan under an insurance policy or other plan
30	providing healthcare coverage in this state is not required to provide
31	coverage for gender transition procedures.
32	
33	
34	
35	
36	